SIGY — Sigyn Therapeutics Cashflow Statement
0.000.00%
- $5.67m
- $7.72m
Annual cashflow statement for Sigyn Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -1.26 | -3 | -2.93 | -4.15 | -3.34 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.343 | 1.21 | 0.782 | 2.26 | 1.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.075 | -0.003 | 0.307 | 0.497 | 1.26 |
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.83 | -1.77 | -1.83 | -1.38 | -0.872 |
Capital Expenditures | — | -0.029 | -0.001 | — | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.011 | 0 | — | — | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.011 | -0.029 | -0.001 | — | — |
Financing Cash Flow Items | — | — | -0.069 | 0.075 | -0.08 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.925 | 2.06 | 1.5 | 1.39 | 0.873 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.084 | 0.257 | -0.333 | 0.003 | 0 |